1
|
Cayuela L, Hernández-Rodríguez JC, Pereyra-Rodriguez JJ, Sendín-Martín M, Cayuela A. Patterns and trends in melanoma mortality in Spain (1999-2022). Clin Transl Oncol 2024:10.1007/s12094-024-03747-3. [PMID: 39367899 DOI: 10.1007/s12094-024-03747-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2024] [Accepted: 09/21/2024] [Indexed: 10/07/2024]
Abstract
AIM To examine melanoma mortality trends in Spanish Autonomous Communities from 1999 to 2022, focusing on gender and age differences. METHODS Data from the National Statistics Institute were used to calculate age-standardized mortality rates (ASMRs). Joinpoint regression identified trend changes. RESULTS Melanoma mortality varied significantly by region, gender, and age. Eastern Spain had higher male mortality, while western regions had lower rates. Asturias had higher female mortality, with lower rates in Andalusia, Extremadura, and Castilla-La Mancha. Men generally exhibited higher ASMRs than women, with variations across regions. While ASMRs remained stable in most areas, Madrid experienced a notable decline (AAPC: - 1.3%). A national trend reversal occurred in 2014 (AAPC: - 1.3%). For individuals aged 45-74 years, Catalonia saw a significant decrease (AAPC: - 1.1%, p < 0.05), whereas Andalusia experienced an increase (APC: 2.1% since 2007). Nationally, ASMRs for this age group declined (AAPC: - 0.7%). Among those aged 75 years and over, ASMRs varied considerably, with increases observed in Andalusia and Aragon. Nationally, male ASMRs rose (AAPC: 1.6% per year), while female rates were stable. Regional disparities were evident, with higher female mortality in the Balearic Islands and fluctuating rates in the Community of Madrid (an increase followed by a decrease after 2015). The gender gap in mortality varied across regions, with some areas showing a narrowing gap and others widening disparities. CONCLUSION Continuous monitoring of melanoma mortality, especially among men and older adults, is crucial. Public health efforts should address regional disparities, improve early detection, and enhance treatment access to optimize outcomes nationwide.
Collapse
Affiliation(s)
- Lucía Cayuela
- Department of Internal Medicine, Hospital Severo Ochoa, Leganés, Spain
| | | | - Jose-Juan Pereyra-Rodriguez
- Unidad de Gestión Clínica de Dermatología, Hospital Universitario Virgen del Rocío, Seville, Spain
- Departamento de Medicina. Facultad de Medicina, Universidad de Sevilla, Seville, Spain
| | - Mercedes Sendín-Martín
- Unidad de Gestión Clínica de Dermatología, Hospital Universitario Virgen del Rocío, Seville, Spain
| | - Aurelio Cayuela
- Unit of Public Health, Prevention and Health Promotion, South Seville Health Management Area, Seville, Spain
| |
Collapse
|
2
|
Soon JA, Franchini F, IJzerman MJ, McArthur GA. Leveraging the potential for deintensification in cancer care. NATURE CANCER 2024:10.1038/s43018-024-00827-9. [PMID: 39304773 DOI: 10.1038/s43018-024-00827-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 09/22/2024]
Affiliation(s)
- Jennifer A Soon
- Cancer Health Services Research, University of Melbourne, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
| | - Fanny Franchini
- Cancer Health Services Research, University of Melbourne, Melbourne, Victoria, Australia
| | - Maarten J IJzerman
- Cancer Health Services Research, University of Melbourne, Melbourne, Victoria, Australia
- Erasmus School of Health Policy & Management, Erasmus University, Rotterdam, the Netherlands
| | - Grant A McArthur
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- Victorian Comprehensive Cancer Centre Alliance, Melbourne, Victoria, Australia
| |
Collapse
|
3
|
Cerezuela-Fuentes P, Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MA, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clin Transl Oncol 2024:10.1007/s12094-024-03583-5. [PMID: 38951438 DOI: 10.1007/s12094-024-03583-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Accepted: 06/20/2024] [Indexed: 07/03/2024]
Abstract
BACKGROUND Novel and highly effective drugs for non-melanoma skin cancer (NMSC) improve patient outcomes, but their high cost strains healthcare systems. Spain's decentralized public health system, managed by 17 autonomous communities (AaCc), raises concerns about equitable access. METHODS A cross-sectional survey (July-September 2023) was sent to Spanish Multidisciplinary Melanoma Group (GEM Group) members to assess access to new drugs. FINDINGS Fifty physicians from 15 Spanish AaCc responded to the survey. Access for drug with approved public reimbursement, Hedgehog inhibitors in basal-cell carcinoma and anti PD-L1 antibody in Merkel carcinoma, was observed in 84% and 86% of centers, respectively. For other EMA-approved treatments, but without reimbursement in Spain access decreased to 78% of centers. Heterogeneity in access was mainly observed intra regions. CONCLUSION Unequal financial support for drugs for NMSC with creates a patchwork of access across Spanish hospitals, with variations even within the same AaCc.
Collapse
Affiliation(s)
- Pablo Cerezuela-Fuentes
- Oncology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Ciudad de Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain
| | - Maria Gonzalez-Cao
- Translational Cancer Research Unit, Dr. Rosell Oncology Institute (IOR), Dexeus University Hospital, C/Sabino Arana, 5, 080028, Barcelona, Spain.
| | | | - Jose Luis Manzano
- Catalan Institute of Oncology (ICO-Badalona), Hospital Germans Trias i Pujol, Badalona, Spain
| | - Cayetana Maldonado
- Dermatology Department, Hospital Universitario de Asturias, Oviedo, Spain
| | - Oriol Yelamos
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Miguel A Berciano-Guerrero
- Oncology Department Hospitales, Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain
| | - Juan Martin-Liberal
- Catalan Institute of Oncology (ICO-Hospitalet), Hospital Duran i Reynals, Barcelona, Spain
| | | | - Enrique Espinosa
- Oncology Department, Hospital Universitario la Paz, Madrid, Spain
- CIBERER, Barcelona, Spain
| | - Ana Drozdowskyj
- Oncology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Ciudad de Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain
| | - Alfonso Berrocal
- Oncology Department, Hospital General de Valencia, Valencia, Spain
| | - Ainara Soria
- Oncology Department, Hospital Ramon y Cajal, Madrid, Spain
| | - Ivan Marquez-Rodas
- Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
| | | | - Maria Quindos
- Medical Oncology Department, Complexo Hospitalario Universitario de A Coruña. Biomedical Research Institute (INIBIC), A Coruña, Spain
| | - Susana Puig
- CIBERER, Barcelona, Spain.
- Dermatology Department, Hospital Clinic Barcelona, University of Barcelona, IDIBAPS, C Villrroel, 08023, Barcelona, Spain.
| |
Collapse
|